GUGLIELMI, Cesare
 Distribuzione geografica
Continente #
NA - Nord America 1.956
EU - Europa 614
AS - Asia 352
SA - Sud America 17
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.944
Nazione #
US - Stati Uniti d'America 1.932
SE - Svezia 175
SG - Singapore 159
IN - India 128
IT - Italia 120
UA - Ucraina 111
FI - Finlandia 86
CN - Cina 59
DE - Germania 41
CA - Canada 24
RO - Romania 24
RU - Federazione Russa 17
AR - Argentina 13
GB - Regno Unito 13
IE - Irlanda 11
BE - Belgio 4
BG - Bulgaria 4
GR - Grecia 4
BR - Brasile 3
JP - Giappone 3
AT - Austria 2
CH - Svizzera 2
HK - Hong Kong 2
TG - Togo 2
CL - Cile 1
EU - Europa 1
NZ - Nuova Zelanda 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 2.944
Città #
Fairfield 215
Chandler 183
Houston 152
Woodbridge 133
Santa Clara 130
Singapore 116
Ashburn 113
Wilmington 97
Princeton 85
Seattle 79
Cambridge 66
Plano 65
Ann Arbor 58
Des Moines 51
Boston 50
Rome 41
Jacksonville 40
Dearborn 39
Beijing 35
Lawrence 35
San Paolo di Civitate 33
Helsinki 23
San Diego 22
Millbury 21
Andover 19
Falls Church 14
Bremen 13
Federal 13
Ottawa 13
Boardman 12
Norwalk 12
Dublin 11
Moscow 10
Toronto 9
Nanjing 8
Falkenstein 6
Hefei 6
Aprilia 5
Columbia 5
Mannheim 5
Southend 5
Bari 4
Brussels 4
Buffalo 4
Cosenza 4
Nettuno 4
Sofia 4
Bühl 3
Madison 3
Redmond 3
San Mateo 3
Trumbull 3
Arnsberg 2
Bern 2
Bisceglie 2
Forno Canavese 2
Giarre 2
Grafing 2
Hong Kong 2
Karatsu 2
Lomé 2
Montréal 2
Munich 2
Nutley 2
Ribeirão Preto 2
Romola 2
Vienna 2
Ancona 1
Arezzo 1
Auckland 1
Broomfield 1
Caserta 1
Cecina 1
Chicago 1
Civitanova Marche 1
Civitavecchia 1
Crawley 1
Felixstowe 1
Forest City 1
Frankfurt am Main 1
Frontone 1
Fuzhou 1
Gandhi Nagar 1
Hangzhou 1
Istanbul 1
Jinan 1
Komatsubaradori 1
Kunming 1
La Spezia 1
Latina 1
Laurel 1
London 1
Los Angeles 1
Muizenberg 1
Nanchang 1
Napoli 1
New York 1
Portland 1
Potters Bar 1
Prineville 1
Totale 2.150
Nome #
Flt3L induces the ex vivo amplification of umbilical cord blood committed progenitors and early stem cells in short term cultures. 80
null 79
Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications 76
pathogenetic and clinical implications of bcl-6 and bcl-2 gene configuration in nodal diffuse large B-cell lymphomas 72
p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis 71
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplant: May We Predict Graft vs Leukemia without Graft vs Host Disease? 70
Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation. may we predict graft-versus-leukemia without graft-versus-host disease? 67
F-MACHOP IN ADVANCED AGGRESSIVE LYMPHOMA 66
Follicular lymphoma international prognostic index 66
Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. 65
Donor Lymphocyte Infusions from Unrelated Donors for Treatment of Relapsed Chronic Myelogenous Leukemia: Importance of Initial Cell Dose. 64
Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation 64
Secondary acute non lymphoid leukemia in patients treated for non Hodgkin's lymphoma: No risk of therapy-related ANLL after PROVECIP schedule 63
Peripheral T cell lymphoma in adults: Morphological and phenotypical study of four cases 63
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 62
Iatrogenic EBV-positive lymphoproliferative disorder with features of EBV+ mucocutaneous ulcer: Evidence for concomitant TCRγ/IGH rearrangements in the Hodgkin-like neoplastic cells 62
Prognostic value of the histologic classification of peripheral T-cell lymphoma: a clinico-pathologic study of 71 HTLV-1 negative cases. 60
Outcome of Patients Developing GVHD after DLI for CML Relapse from HLA-Identical Sibling or VUD HSCT. 59
S-100+ lymph node neoplasm. Report of a case with histological AL and immunological features intermediate between T cell lymphoma and malignant histiocytosis. 59
Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP) 58
Acute lymphoblastic leukemia (ALL) primary refractory or in first relapse: results in children and adults over a 20-year period. 57
Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party. 56
Peripherally Inserted Central Catheter (PICC) Power Groshong 5 Fr device for management of peripheral blood stem cell collection and transplantation in haematological patients: a single centre study from the Rome Transplant Network 55
Flt3L enhances the early stem cell compartment after ex vivo amplification of umbilical cord blood CD34+ cells. 53
Heterogeneity of TdT+, HLA-DR+ acute leukaemia: immunological, immunocytochemical and clinical evidence of lymphoid and myeloid origin. 53
DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma. 51
Decreasing impact of relapse on death rate after allogeneic haematopoietic stem cell transplant in patients with chronic myeloid leukaemia: a multi-state modelling study 50
P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non Hodgkin Lymphoma 49
Acute lymphoblastic leukemia (ALL) primary refractory or in first relapse: results in children and adults over a 20-year period 49
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 49
p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome 48
Decreasing Impact of Relapse on Death Rate after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Chronic Myeloid Leukemia: a multi-state modelling study. 48
A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas 47
B-cell acute lymphoid leukemia (ALL) with lymphoblastic expressing surface immunoglobulin only at relapse 46
Unrelated cord blood transplant (CBT) in patients with high risk leukaemia: a long-term follow-up 45
Transplant Centre Experience and Patient Selection Are the Key Elements Associated with Outcome of RIC and MAC HSCT for CML. 45
Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. 44
I linfomi non-Hodgkin 43
Impiego sequenziale di ARA-C ad alte dosi ed asparaginasi (HIDAC+ASP) nel trattamento di leucemie acute e linfomi maligni in fase avanzata. 43
A prospective molecular study of chimerism in patients with hematologic malignancies receiving unrelated cord blood or bone marrow transplants: detection of mixed chimerism predicts graft failure with or without early autologous reconstitution in cord blood recipients. 43
May we predict a “pure” Graft versus Leukemia Effect after Donor Lymphocyte Infusions for chronic myeloid Leukemia relapsing after allogeneic Stem Cell Transplant ? 40
Clinical relevance of immunological markers in acute lymphoblastic leukemia. 40
Immunophenotype and clinical presentation in T-cell acute lymphoblastic leukemia 40
Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update. 37
Cord blood transplant (CBT) from unrelated mismatched donor in high risk (HR) leukemia 37
Unrelated cord blood transplant (CBT) in patients with high risk leukemia: A long-term follow-up. 35
Determinazione citofluorimetrica del contenuto di DNA cellulare nelle leucemie acute 34
Unrelated cord blood transplant (CBT) in patients with high risk leukemia: a long-term follow-up. 33
Time to relapse has prognistic value in patients with aggressive Lymphoma enrolled onto the Parma trial. 33
Aneuploidy determined by flow citometry (FCM) in acute lymphoblastic leukemia (ALL): clinical significance in 99 patients. 31
Trattamento del linfoma linfoblastico: risultati di due diversi schemi di polichemioterapia intensiva 31
Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. 31
HLA-C and HLA-DQB1 compatibility in unrelated cord blood transplants 30
Immunophenotype of adult and childhood acute lymphoblastic leukemia: Changes at 1st relapse and clinico-prognostic implications. 28
Recombinant alpha interferon in the treatment of low-grade non-Hodgkin's lymphoma: results of a cooperative phase II trial in 31 patients. 28
Outcome of patients developing GVHD after DLI for CML relapse post HSCT: a retrospective study from the CLWP of the EBMT 25
Three Cases of Therapy-related Acute Myeloid Leukaemia In Patients With Multiple Sclerosis: the Role of Arsenic Trioxide In the Treatment of Secondary Apl 24
THE F-MACHOP REGIMEN IN ADVANCED DIFFUSE AGGRESSIVE LYMPHOMAS - SUMMARY OF 10 YEARS EXPERIENCE AT A SINGLE INSTITUTION 21
The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results. 21
Trapianto di sangue da cordone ombelicale (SCO) da donatore non familiare in pazienti con leucemia acuta ad alto rischio 17
Ricerca di unità di sangue di cordone ombellicale (SCO) da donatore non correlato per trapianto allogenico in pazienti affetti da leucemia ad alto rischio 16
Umbilical cord blood (UCB) transplant from unrelated mismatched donor in patients with high risk (HR) leukemia. 15
Il trapianto di cellule staminali da sangue di cordone ombellicale 14
Search for unrelated cord blood (CB) unit for transplantation of high risk leukemic patients 13
Outcome of patients developing GvHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT 2
Totale 2.976
Categoria #
all - tutte 8.581
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.581


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020346 0 0 0 0 0 85 61 63 49 56 18 14
2020/2021154 30 27 6 13 1 8 0 22 12 19 16 0
2021/2022626 0 33 42 52 98 18 10 58 43 55 68 149
2022/2023703 149 126 47 73 55 114 15 46 50 4 12 12
2023/2024184 24 25 7 9 10 4 5 8 3 34 31 24
2024/2025296 11 54 40 9 93 89 0 0 0 0 0 0
Totale 2.976